Introduction: Dabigatran, as compared with warfarin, was associated with lower
. One of the advantages of dabigatran over warfarin is that there is no need for drug level or INR monitoring due to predictable pharmacokinetics and pharmacodynamics. Dabigatran, as compared with warfarin, was associated with lower rates of stroke and systemic embolism with similar rates of major hemorrhage. 2 Dabigatran has less intracranial hemorrhage, but concerns have been raised regarding a significantly higher risk of gastrointestinal bleeding (GIB) with dabigatran as compared to warfarin with relative risk of 1.5. 2,3 Meta-analysis of 5 randomized controlled trials confirmed a higher GIB in dabigatran compared to warfarin (relative risk, 1.51; 95% CI, 1.23-1.84). 3 Recent meta-analysis of observational studies also showed 18%
increased risk of GIB in dabigatran 150 mg twice daily compared to warfarin.
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There are 2 possible explanations regarding why dabigatran caused more GIB than warfarin. First, dabigatran etexilate, which is a prodrug, has limited absorption from GI tract into portal vein system with only 3-7% bioavailability. 5 This low bioavailability is partly because a P-glycoprotein transport system actively pumps dabigatran etexilate from enterocytes back into the GI tract, 6 which is later hydrolyzed by enterocyte esterase into active form and causes local anticoagulant effect. Secondly, dabigatran etexilate absorption is dependent on an acid environment; therefore, it is formulated together with tartaric acid to reduce its variability. This acidity may partly explain the increased incidence of dyspeptic symptoms and the increased risk of GIB. Rivaroxaban and edoxaban also have significantly higher GIB rates when compared to warfarin, but the mechanisms are not well understood.
Dabigatran increased risk of both upper GIB and lower GIB.
From the RE-LY trial, 53% of major GIB occurred in the lower GI tract and 47% occurred in the upper GI tract. 7 There are limited data regarding effective strategy to reduce GIB among dabigatran users.
Proton pump inhibitor or H2-receptor antagonist (PPI/H2RA) has been shown to reduce upper GIB in patients on warfarin, aspirin, or
NSAIDs. 8 Therefore, we hypothesized that PPI/H2RA may reduce a significant portion of GIB events from dabigatran by protecting stomach and duodenal mucosa from local anticoagulation effect, irritation from tartaric acid, and concomitant use of aspirin or NSAIDs.
The aim of this study was to identify risk factors associated with increased GIB in patients with atrial fibrillation taking dabigatran and whether PPI/H2RA can prevent dabigatran-related GIB in a realworld observational cohort.
| ME TH ODS
This is a single-center retrospective cohort study of patients with atrial fibrillation who have ever taken dabigatran for thromboprophylaxis. We identified atrial fibrillation patients using ICD-9 coding at 
| RESULTS
A total of 247 patients were identified between October 2010 and February 2013. Mean age was 72 years, and 48.2% were female.
Baseline characteristics between groups were similar, except for history of GU/gastritis/GERD, history of stroke, alcohol abuse, and HAS-BLED score which were higher in the PPI/H2RA group (Table 1) . Mean HAS-BLED score in PPI/H2RA users was 2.1, which was significantly higher than that of non-PPI/H2RA users (1.6).
There were 10 of 247 (4.0%) patients who developed GIB, and all of them were hospitalized. Among 10 GIB cases, 4 were upper GIB, 5 were lower GIB, and 1 was unknown due to refused endoscopy/colonoscopy. Median time to first GIB event was 204 days after the start of dabigatran use (minimum 39 days, maximum 769 days). Five patients required transfusion of 2 or more units of PRBCs, and 3 patients developed serious complications (shock, acute kidney injury, endotracheal intubation, or death).
Rate of GIB was 6.5% in PPI/H2RA users, as compared with 2.6% with non-PPI/H2RA users (P = .184) ( Table 2 ). After adjustment for baseline differences (history of GU/gastritis/GERD, history of stroke, alcohol use, and mean HAS-BLED score), PPI/H2RA use was still not associated with reduction in the odds of GIB (adjusted odds ratio, 1.34; 95% CI, 0.30-6.10; P = .70). Severity and complications from GIB comparing between the 2 groups were not different.
There was no difference in prevalence of hemorrhagic or ischemic stroke between the 2 groups.
Univariate analysis demonstrated that history of GIB within 1 year prior to initiation of dabigatran, corticosteroid use, and a high HAS-BLED score were risk factors for GIB ( who did not use corticosteroids (odds ratio, 4.65; 95% CI, 1.12-19.39; P = .035). Higher HAS-BLED score was also associated with higher risk of GIB. According to the ROC curves from our data, a HAS-BLED score cutoff of 3 or more was an optimal cutoff value for predicting risk of GIB with 70% sensitivity and 80% specificity (AUC = 0.722, P = .018) (Figure 1 ). So, we used HAS-BLED score of ≥3 in univariate analysis which showed GIB rate of 12.7%, as compared to 1.6% in the lower HAS-BLED score group (odds ratio, 9.19; 95% CI, 2.29-36.85; P < .01).
After adjusted with multivariate analysis, corticosteroid use was not associated with increased GIB (odds ratio, 4.30; 95% CI, 0.81-22.79; P = .087). Only history of GIB within 1 year prior to dabigatran initiation and HAS-BLED score ≥3 were still associated with increased GIB, with odds ratio of 25.14 (95% CI, 2.85-221.47; P < .01) and 5.85 (95% CI, 1.31-26.15; P = .021), respectively (Table 4) .
| DISCUSSION
A large trial and a meta-analysis of randomized controlled trials have consistently shown that dabigatran increased the risk of GIB compared to warfarin. 2,3 One may ask, given this inherited problem of higher GIB risk, why dabigatran is still being used. There are a few differences between dabigatran and other DOACs: (i) Dabigatran is the only DOAC that has FDA-approved reversal agent, idarucizumab;
(ii) it is dialyzable, while apixaban, edoxaban, and rivaroxaban are not; (iii) it may be used in liver disease because 80% of total clearance is from kidney, while apixaban, edoxaban, and rivaroxaban should be avoided in patients with Child-Pugh B or C; and (iv) only apixaban and dabigatran met superiority in preventing stroke or systemic embolism compared to warfarin, notwithstanding that all trials were designed as noninferiority studies.
In our study, GIB rate in dabigatran users was 4.0%, which was higher compared to the 1.51% in the RE-LY trail 2 and 1.54% in an additional follow-up study, 10 but similar to the 3.1% in other studies. [11] [12] [13] Our study consisted of high-risk populations that would have been excluded from the RE-LY study, 2 hence reflecting a "realworld" practice. These high-risk patients had GIB within 1 year prior to dabigatran initiation (2.0%), alcohol use (7.4%), CrCl <30 mL/min/ 1.73 m 2 (4.0%), and abnormal liver function (2.4%).
PPI/H2RA did not reduce GIB events in our study. This is in contrast to the Chan et al 14 study which showed that use of PPI/H2RA
was associated with reduced risk of GIB, with the caveat that risk reduction was significant only for upper GIB and in patients with prior history of peptic ulcers or GIB. The differences in the results are possibly due to (i) smaller sample size in our study or (ii) because our populations have significantly higher risk of GIB. Prior history of GIB or peptic ulcers was 51.8% in our study as compared to 13.9% in Chan's study. We had 7.4% alcohol use and 2.4% abnormal liver function patients as compared to none mentioned in Chan's study.
Renal disease in Chan's study was 5.1%-however, GFR was not Multivariate analysis showed that HAS-BLED score ≥3 and prior history of GIB within 1 year significantly increased the risk of GIB with odds ratio of 5.85 and 25.14, respectively. HAS-BLED has been widely validated for risk of major bleeding in AF and non-AF patients receiving warfarin as well as aspirin therapy. 9, 16, 17 However, data regarding HAS-BLED score in predicting GIB in patients taking DOACs are limited. The Danish National Patient Registry used HAS-BLED score to evaluate intracranial hemorrhage, not GIB, in patients taking DOACs. 18 One study showed that HAS-BLED score offers predictive capacity for overall bleeding in mixed population of warfarin and fixed-dose ximelagatran users. 19 Another retrospective study found a modified HAS-BLED score was not predictive of risk of major bleeding in patients taking dabigatran or rivaroxaban. 20 Most of the studies that specifically evaluate risks for GIB from dabigatran did not collect or elaborate on HAS-BLED score data.
2,14
There is 1 dabigatran study that described HAS-BLED score in baseline characteristics with HAS-BLED score, but it did not compare or analyze HAS-BLED score between the GIB group and the no-GIB group. 21 We are the first to use HAS-BLED score to specifically look at GIB among dabigatran users, and to demonstrate it as an independent risk factor for GIB. Prior history of GIB within 1 year is also demonstrated here as an independent risk factor for GIB, which is consistent with other dabigatran 14 and rivaroxaban studies. 22 NSAIDs or aspirin use has been shown to increase the risk of GIB in a few studies predating the dabigatran era. [23] [24] [25] Although
NSAIDs or aspirin use alone did not increase the risk of GIB in our study, it is one of the factors incorporated in HAS-BLED score and thus should be taken into account when starting dabigatran. One study showed corticosteroids as a risk factor for GIB or perforation. 26 In our study, concurrent steroid use demonstrated a trend toward increased risk of GIB, although not statistically significant. Limitations of this study include selection bias, which is the nature of retrospective review studies. We had a small sample size, therefore possibly leading to inadequate statistical power. Although our study is not a randomized controlled trial, it provided useful information regarding how to choose the right patient for the right medicine.
| CONCLUSION S
In this real-world practice observation, PPI/H2RA use was not associated with reduced GIB events. HAS-BLED score ≥3 and prior history of GIB within 1 year are independent risk factors for GIB in dabigatran users. Possible strategies to reduce GIB rate in these high-risk population include correcting modifiable HAS-BLED risk factors, reducing dabigatran dose, and using other agents with less GIB risk.
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